Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

SMRT Sequencing of Human Genomes to be Showcased at AGBT Conference

Monday, February 12, 2018

MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California Inc., (Nasdaq:PACB) today announced its Single Molecule, Real-Time (SMRT®) Sequencing technology will be demonstrated in several presentations and posters at the annual Advances in Genome Biology & Technology (AGBT) conference taking place February 12-15 in Orlando. PacBio is also an official sponsor of this year’s meeting.

The poster and podium presentations will demonstrate how, by using the latest advances in SMRT Sequencing, it is now possible to conduct large cohort human genome sequencing studies to detect structural variants that are known to cause rare disease or contribute to common traits. These larger structural variants are now understood to be broadly missing from variant databases built with short-read DNA sequencing methods, and may account for a sizable fraction of the causative genetic variants underlying health and disease traits. 

For example, a talk from customer Alexander Hoischen, Ph.D., of Radboud University Medical Center in the PacBio workshop (Thursday, February 15, at 9:40 a.m.) will focus on the use of SMRT Sequencing to detect structural variants in rare diseases in work associated with the recently launched SOLVE-RD research program. The consortium aims to apply new long-read sequencing methods to 500 previously unsolved rare disease cases. 

PacBio will host a series of “Lightning Talks” in the company’s hospitality suite (Columbia Room):

  • Tuesday, February 13, 8:30 a.m.
    What’s New with the Sequel® System? More Data, Better Biology Jonas Korlach, Ph.D., CSO
  • Tuesday, February 13, 10:45 a.m.
    PacBio® Long-Read WGS for Structural Variant Discovery Aaron Wenger, Ph.D., Principal
  • Wednesday, February 14, 10:30 a.m.
    No-Amp Targeted Enrichment & SMRT Sequencing of Repeat-Expansion Disease Causative Genomic Regions Jonas Korlach, Ph.D., CSO

In a poster presentation entitled “Population-Scale Discovery of Structural Variants with PacBio SMRT Sequencing,” Aaron Wenger, Ph.D., will describe how combining the latest SMRT Sequencing technology advances with improved variant calling is making population-scale human genome sequencing practical and cost-effective for high-throughput sequencing labs.

Other posters and presentations will illustrate the usefulness of SMRT Sequencing data for full-length transcript profiling with the Iso-Seq® method, multiplexed microbial genome sequencing, agbio, and other applications.

“As we continue to enhance the throughput and performance of our Sequel System, it is exciting to see how this platform is powering new discoveries that were never possible with other sequencing technologies,” said Kevin Corcoran, Senior Vice President of Market Development for PacBio. “We look forward to the AGBT posters and presentations through which our customers will share their impressive work and demonstrate the unparalleled value of SMRT Sequencing for resolving even the most challenging genomic regions.”

A complete list of PacBio-related talks and company-sponsored special events at AGBT is
available here
. For more information, please visit https://www.pacb.com/.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, quality or performance of, or benefits of using, products or technologies, future product enhancements, the suitability or cost-effectiveness of products for particular applications or projects and
other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.


Media: Nicole Litchfield415.793.6468

Investors:Trevin Rard650.521.8450


Primary Logo

Source: Pacific Biosciences, Inc.

News Provided by Acquire Media